Low dose of emicizumab could be as effective as standard dose against Haemophilia A, according to a study led by the Indian ...

Early results from the Phase I/II NXTAGE trial show that NXT007 may achieve hemostatic normalization in patients with ...

The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...

Mim8 (denecimig) prophylaxis was well-tolerated in FRONTIER5 phase 3 switch trial in people with haemophilia A ·         New FRONTIER5 data shows direct switch to Mim8 prophylaxis treatment from ...

In Hooghly district, haemophilia injections have not been available at either Chinsurah Imambara Hospital or Arambagh Medical ...

The Indian Council of Medical Research's National Institute of Immunohaematology (ICMR's NIIH) has developed a cost-effective ...

New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated with no safety ...

Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show ...

A patient at Guy’s and St Thomas’ recently received the first treatment in the UK of a new, potentially life-changing ...

A gene transfer approach to treating the bleeding disorder hemophilia B remains safe and effective long-term, as scientists ...

According to a new study in Haemophilia, up to 60% of patients with severe HA have no known family history, making early ...

Subsequent studies by other investigators confirmed those early results, ultimately leading to the FDA approval of ...